Drugs / TCRT-ESO-A2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04878484 | Aug 2021 → Oct 2022 | neoplasm | Athenex, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-01-02 | PharmaEssentia | Regulatory Material Information - Update on the Company's IND Application ofPhase I Clinical Trial of TCRT-ESO-A2-TW in Patientswith Advanced Solid Tumors to TFDA pharmaessentia.com ↗
MOHW was not able to agree to the implementation. |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCRT-ESO-A2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04878484 ↗ |
| Modality | Cell therapy | “autologous cell therapy” NCT04878484 ↗ |
| Route | Intravenous | “Subjects will receive their TCRT-ESO-A2 cell product on Day 1 (recommend Monday) as an IV infusion over approximately 30 minutes.” NCT04878484 ↗ |